Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

Gastroenterology

Volumn 120, Issue 7, 2001, Pages 1713-1719

  Mann, Moss ^a   Sheng, Hongmiao ^a   Shao, Jinyi ^a   Williams, Christopher S ^a,b   Pisacane, Paul I ^a   Sliwkowski, Mark X ^a   DuBois, Raymond N ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NEU DIFFERENTIATION FACTOR; RECOMBINANT HEREGULIN BETA1 PROTEIN; RECOMBINANT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035004747     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.24844     Document Type: Article

References (45)

1. The biology and treatment of progranulocytic leukemia
2. New directions in the treatment of colorectal cancer: A look to the future
3. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
4. Localization of cyclooxygenase-2 in human sporadic colorectal adenoma
5. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
6. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
7. The role of cyclooxygenases in inflammation, cancer and development
8. Translational studies on COX-2 inhibitors in the prevention and treatment of colorectal cancer
9. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
10. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
11. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
12. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
13. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
14. The ErbB signaling network: Receptor heterodimerization in development and cancer
15. The ErbB receptors as targets for breast cancer therapy
16. Epidermal growth factor receptor (EGFR); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
17. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
18. Development of Herceptin
19. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
20. Nonclinical studies addressing the mechanism of action of Herceptin® (trastuzumab)
21. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer
22. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas
23. Combinatorial chemoprevention of intestinal neoplasia
24. Combinations for cancer prevention
25. Isolation and characterization of multiple cell types from a single human colonic carcinoma: Tumorigenicity of these cell types in a xenograft system
26. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness
27. β-Heregulin: A novel heregulin isoform that is an autocrine growth factor for the human breast tumor cell line, MDA-MB-175
28. Coexpression of ErbB2 and ErbB3 proteins reconstitutes a high affinity receptor for heregulin
29. A novel method for real time quantitative PCR
30. Real time quantitative PCR
31. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
32. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
33. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
34. Regulation of cyclooxygenase-2 pathway by HER2 receptor
35. Lessons from hereditary colorectal cancer
36. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
37. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
38. Host cyclooxygenase-2 modulates carcinoma growth
39. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms
40. Overexpression of HER2/new in solid tumors: An immunohistochemical survey
41. EGF receptor activation induces nuclear targeting of COX-2, basolateral release of prostaglandins and mitogenesis in polarizing colon cancer cells
42. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells
43. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention
44. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
45. Site-directed irreversible inhibitors of the ErbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer